Restoration of Axon Conduction and Motor Deficits by Therapeutic Treatment with Glatiramer Acetate

Restoration of Axon Conduction and Motor Deficits by Therapeutic Treatment with Glatiramer Acetate

Glatiramer acetate (GA; Copaxone) is an approved drug for the treatment of multiple sclerosis (MS). The underlying multifactorial anti-inflammatory, neuroprotective effect of GA is in the induction of reactive T cells that release immunomodulatory cytokines and neurotrophic factors at the injury sit...

Full description

Bibliographic Details
Main Authors:	Moore, Spencer, Khalaj, Anna J, Patel, Rhusheet, Yoon, JaeHee, Ichwan, Daniel, Hayardeny, Liat, Tiwari-Woodruff, Seema K
Format:	Online
Language:	English
Published:	BlackWell Publishing Ltd 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305217/

Similar Items

Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis
by: Moore, Spencer, et al.
Published: (2013)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
by: Meca-Lallana, Jose Eustasio, et al.
Published: (2015)

Glatiramer acetate treatment negatively regulates type I interferon signaling
by: Molnarfi, Nicolas, et al.
Published: (2015)

T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment
by: Chen, Li, et al.
Published: (2015)

Neuroprotective Effect of Combination Therapy of Glatiramer Acetate and Epigallocatechin-3-Gallate in Neuroinflammation
by: Herges, Katja, et al.
Published: (2011)

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial
by: Arnold, Douglas L., et al.
Published: (2013)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
by: Fernández, Oscar
Published: (2012)

CD8+ T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease
by: Tyler, Andrew F., et al.
Published: (2013)

Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients
by: Thamilarasan, Madhan, et al.
Published: (2013)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
by: Achiron, Anat, et al.
Published: (2009)

Glatiramer acetate does not protect from acute ischemic stroke in mice
by: Kraft, Peter, et al.
Published: (2014)

Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
by: Towfic, Fadi, et al.
Published: (2014)

Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
by: Izquierdo, Guillermo, et al.
Published: (2015)

Metabolic response to glatiramer acetate therapy in multiple sclerosis patients
by: De Riccardis, Lidia, et al.
Published: (2016)

Glatiramer acetate treatment negatively regulates type I interferon signaling
Published: (2015)

Glatiramer acetate desensitisation in multiple sclerosis patients - the case report
by: Novotna, Bronislava, et al.
Published: (2014)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
by: Caporro, Matteo, et al.
Published: (2014)

Potassium channel blockers restore axonal conduction in CNS trauma and diseases
by: Page, Jessica C., et al.
Published: (2016)

The potential neuroprotective effects of weekly treatment with glatiramer acetate in diabetic patients after panretinal photocoagulation
by: Mitne, Somaia, et al.
Published: (2011)

29 gauge needles improve patient satisfaction over 27 gauge needles for daily glatiramer acetate injections
by: Glenski, Stephen, et al.
Published: (2009)

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
by: Waschbisch, Anne, et al.
Published: (2011)

Glatiramer Acetate Treatment Increases Stability of Spinal Synapses and Down Regulates MHC I during the Course of EAE
by: Scorisa, Juliana M., et al.
Published: (2011)

Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
by: Sanchez-de la Rosa, Rainel, et al.
Published: (2013)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
by: Oreja-Guevara, Celia, et al.
Published: (2012)

Nanolipodendrosome-loaded glatiramer acetate and myogenic differentiation 1 as augmentation therapeutic strategy approaches in muscular dystrophy
by: Afzal, Ehsan, et al.
Published: (2013)

Glatiramer Acetate Increases Phagocytic Activity of Human Monocytes In Vitro and in Multiple Sclerosis Patients
by: Pul, Refik, et al.
Published: (2012)

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
by: Giannini, Marta, et al.
Published: (2012)

Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
by: Bergvall, Niklas, et al.
Published: (2014)

Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010
by: Oleen-Burkey, MerriKay, et al.
Published: (2014)

Glatiramer Acetate Treatment Increases Stability of Spinal Synapses and Down Regulates MHC I during the Course of EAE
by: Juliana M. Scorisa, Camila M. Freria, Sheila C. Victorio, Roberta Barbizan, Renata G. Zanon, Alexandre L. R. Oliveira
Published: (2011-01-01)

Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone
by: S. Melamed-Gal, et al.
Published: (2018-09-01)

Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon
by: Fernández-Fournier, Mireya, et al.
Published: (2015)

Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis: A Case Report
by: Onmez, Attila, et al.
Published: (2013)

The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing‐Remitting Multiple Sclerosis
by: Zivadinov, Robert, et al.
Published: (2015)

Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection—a case report
by: Zecca, Chiara, et al.
Published: (2015)

The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients
by: Rovituso, Damiano M., et al.
Published: (2015)

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
by: Sánchez-de la Rosa, Rainel, et al.
Published: (2015)

Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1
by: Janssen, Antonia, et al.
Published: (2015)

Flare Up Reaction During Provocation Test to Glatiramer Acetate in a Patient With Allergy to Interferon Beta1a
by: Minciullo, Paola L., et al.
Published: (2014)

Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome
by: Kuzina, Ekaterina, et al.
Published: (2014)